Fate Therapeutics (FATE) Enterprise Value (2012 - 2026)
Fate Therapeutics (FATE) posted Enterprise Value of -$174.8 million for Q1 2026, up 14.16% on a QoQ basis from -$203.7 million in Q4 2025, and up 27.29% year-over-year from -$137.3 million in Q1 2025.
Fate Therapeutics (FATE) Enterprise Value (2012 - 2026) Analysis & Trends
Fate Therapeutics' Enterprise Value history runs 15 years deep, the most recent figure standing at -$174.8 million for Q1 2026.
- Quarterly Enterprise Value rose 27.29% year-over-year to -$174.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$174.8 million (up 27.29% YoY) and the FY2025 annual result came in at -$203.7 million, up 27.02% from the prior year.
- Enterprise Value was -$174.8 million for Q1 2026 at Fate Therapeutics, up from -$203.7 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$174.8 million in Q1 2026 and bottomed at -$573.8 million in Q1 2022.
- A 5-year average of -$344.5 million and a median of -$315.2 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value grew 6.2% — and 2025, when it surged 37.31%.
- Fate Therapeutics' Enterprise Value stood at -$436.2 million in 2022, then gained by 27.75% to -$315.2 million in 2023, then advanced by 11.46% to -$279.1 million in 2024, then gained by 27.02% to -$203.7 million in 2025, then increased by 14.16% to -$174.8 million in 2026.
- Business Quant data shows FATE's Enterprise Value at -$174.8 million in Q1 2026, -$203.7 million in Q4 2025, and -$215.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Fate Therapeutics | 302.48 Mn | 302.48 Mn | - | -174.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -174.82 Mn |
| Dec 31, 2025 | -203.66 Mn |
| Sep 30, 2025 | -215.42 Mn |
| Jun 30, 2025 | -222.83 Mn |
| Mar 31, 2025 | -240.43 Mn |
| Dec 31, 2024 | -279.07 Mn |
| Sep 30, 2024 | -296.92 Mn |
| Jun 30, 2024 | -304.88 Mn |
| Mar 31, 2024 | -383.54 Mn |
| Dec 31, 2023 | -315.18 Mn |
| Sep 30, 2023 | -349.73 Mn |
| Jun 30, 2023 | -377.94 Mn |
| Mar 31, 2023 | -408.90 Mn |
| Dec 31, 2022 | -436.23 Mn |
| Sep 30, 2022 | -505.14 Mn |
| Jun 30, 2022 | -568.85 Mn |
| Mar 31, 2022 | -573.77 Mn |
| Dec 31, 2021 | -615.91 Mn |
| Sep 30, 2021 | -678.70 Mn |
| Jun 30, 2021 | -695.60 Mn |